• UGI USER
  • May 02, 2024
  • 4 Likes
  • 1 Comments

“SC PETITION REQUESTS EXPERT PANEL TO PROBE COVISHIELD VACCINE’S SAFETY.”

Why in the news?

“Supreme Court petition seeks expert panel to investigate Covishield vaccine’s safety after AstraZeneca’s blood clot concerns.”

source:slideserve

About Plea for Vaccine Safety Probe:

  • Advocate Vishal Tiwari filed a petition in the Supreme Court concerning the safety of the Covishield vaccine.
  • The petition requests the formation of an expert medical panel to investigate the vaccine’s risk factors.
  • AstraZeneca, the developer of the vaccine, acknowledged in a U.K. court that its AZD1222 vaccine, manufactured by the Serum Institute of India as Covishield, may lead to low platelet counts and blood clot formation in rare instances.
About  AstraZeneca:

  • Global biopharmaceutical company.
  • Prioritises science-led innovation to enhance medicine’s impact on patients.
  • Aims to transform healthcare through scientific advancements.

Understanding Covishield :

Covishield Origins:

  • Developed by AstraZeneca and Oxford University in 2020 amidst the Covid-19 pandemic.
  • Produced in India by the Serum Institute of India (SII) under the name Covishield.

Covishield in India:

  • The Indian government advised caution for individuals with low platelet counts while administering Covishield.
  • Vaccination started in India on January 16, 2021, with a reported rate of 0.61 thromboembolic events per million doses.

What is Thrombosis with Thrombocytopenia Syndrome (TTS)?

  • Rare condition characterised by blood clot formation (thrombosis) and low blood platelet count (thrombocytopenia).
  • Associated with certain COVID-19 vaccines, particularly those using adenovirus vectors like Covishield.
  • Adenovirus vectors are efficient gene delivery vehicles commonly used in gene therapy, vaccination, and cancer treatment.